Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
These Novartis PDX models have been previously published in the Nat Med. 2015 study of using PDX models in high-throughput screening to predict clinical trial drug response. More recently,
a selection of these models were used in a study of FGFR inhibitors.
See our detailed model lists for more information about our solid tumor models. In vivo growth and drug treatment response data and CNV data are also available
for these models. RNA-seq data, whole-exome seq data, and low-pass WGS data are available on cBioPortal. HLA data inferred from RNA-seq data is also available here.
Learn more about ordering and licensing these models, or email us at firstname.lastname@example.org to submit an inquiry.
See CPDM's SOPs for working with these models for guidance.